drugset
drugset / Trial / NCT01590459

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

NCT01590459 ↗

Phase 2 Completed 359 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the safety and efficacy of VX-509, an oral JAK3 inhibitor, for treatment of subjects with active RA who have had an inadequate response to Methotrexate.

Timeline

Start
2012-04
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject decernotinib Small molecule 100 mg Oral
Subject decernotinib Small molecule 150 mg Oral
Subject decernotinib Small molecule 200 mg Oral

Indications

rheumatoid arthritis